PrinJohnson Biopharm is an emerging pharmaceutical company that is engaged in generic product development, registration, marketing and sales for the global market. The company was originally wholly owned by Huahai Pharmaceutical, a publicly-listed pharmaceutical company in China.
In June 2014, Milestone Capital was the lead investor in the Series B equity financing for PrinJohnson Biopharm.
